Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Vaccino vettoriale AD26.COV2.S anti COVID-19

Jcovden (ex COVID-19 Vaccine Janssen)

Bibliografia - Quali fonti bibliografiche per Vaccino vettoriale AD26.COV2.S anti COVID-19?

  1. Anywaine Z. et al., J. Infect. Dis., 2019, 220 (1), 46.

  2. Barouch D.H. et al., lancet, 2018, 392 (10143), 232.

  3. European Medicines Agency – EMA, COVID-19 Vaccine Janssen – Riassunto Caratteristiche di Prodotto, 2021, 11 marzo https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_it.pdf (accesso: marzo 2021).

  4. Food and Drug Administration – FDA, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 2007, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical (accesso: febbraio 2021).

  5. FDA Briefing Document, Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19, 2021, 26 February http://www.quotidianosanita.it/allegati/allegato567003.pdf (accesso febbraio 2021).

  6. Food and Drug Administration – FDA, 2021a, 1 marzo https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine (accesso: marzo 2021).

  7. Food and Drug Administration – FDA, FDA Statement, Join CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine, 2021, April 13 https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine (accesso: aprile 2021).

  8. Johnson&Johnson, 2021, 29 gennaio https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial (accesso: febbraio 2021).

  9. National Vaccine Injury Compensation Program, Vaccine Injury Table, Revised and Effective, 2017, March 21 https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/vaccine-injury-table.pdf (accesso: marzo 2021).

  10. Sadoff J. et al., NEJM, 2021, Jan 13;NEJMoa2034201.

  11. Studio clinico NCT04505722, 2021 https://clinicaltrials.gov/ct2/show/NCT04505722.

  12. Williams K. Et al., J. Infect. Dis., 2020, 222 (6), 979.